文献速递心律失常冠心病血脂与心血管预防

新发心房颤动患者抗血小板单药治疗的特征:GARFIELD-AF 注册研究

Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.
PubMed 文献 · Eur Heart J · 2018-01-01

该研究基于 GARFIELD-AF 注册研究,分析 2010 至 2016 年间 35 个国家 51 270 例新发心房颤动且至少有一项卒中危险因素的患者,其中 20.7% 接受抗血小板单药治疗。与抗凝单药治疗者相比,抗血小板单药者更多为中国患者、持续性房颤、合并冠心病或血管疾病、出血史或痴呆,且随时间推移非适应证使用下降但 2015 至 2016 年仍有约半数无抗血小板指征。

要点

  • 新发房颤中约五分之一仍接受抗血小板单药治疗,多数 CHA2DS2-VASc≥2。
  • 抗血小板单药者常合并冠心病、血管疾病、出血史或痴呆,中国患者比例高。
  • 随时间抗血小板单药治疗下降,但近年仍有约半数无抗血小板指征。

核心结论

  • 新发房颤中抗血小板单药治疗处方已减少,但至今仍有相当比例无抗血小板指征。

研究设计与样本

  • GARFIELD-AF 为注册研究,纳入 2010 至 2016 年 35 个国家 51 270 例新发(≤6 周)房颤且至少有一项研究者确定的卒中危险因素患者,分五个连续队列。

主要发现

  • 总体 20.7% 接受抗血小板单药,52.1% 接受抗凝单药,14.1% 接受抗血小板加抗凝。
  • 抗血小板单药者中 82.5% 为 CHA2DS2-VASc≥2,抗凝单药者中 86.8% 为 CHA2DS2-VASc≥2。
  • 与中国患者(对比白人)相关的比值比为 2.73,持续性房颤 1.32,冠心病史 2.41,其他血管疾病 1.67,出血史 2.11,痴呆 1.81。
  • 年龄≥75 岁每增加 5 岁比值比 1.24,55-75 岁每增加 5 岁比值比 0.86。
  • 阵发性房颤 0.67,永久性房颤 0.57,栓塞史 0.56,饮酒 0.90;抗血小板单药随队列下降 P<0.0001。

临床怎么用

  • 临床应避免将抗血小板单药作为房颤卒中预防的替代,尤其对无抗血小板指征者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Current atrial fibrillation (AF) guidelines discourage antiplatelet (AP) monotherapy as alternative to anticoagulants (ACs). Why AP only is still used is largely unknown. METHODS AND RESULTS: Factors associated with AP monotherapy prescription were analysed in GARFIELD-AF, a registry of patients with newly diagnosed (≤6 weeks) AF and ≥1 investigator-determined stroke risk factor. We analysed 51 270 patients from 35 countries enrolled into five sequential cohorts between 2010 and 2016. Overall, 20.7% of patients received AP monotherapy, 52.1% AC monotherapy, and 14.1% AP + AC. Most AP monotherapy (82.5%) and AC monotherapy (86.8%) patients were CHA2DS2-VASc ≥2. Compared with patients on AC monotherapy, AP monotherapy patients were frequently Chinese (vs. Caucasian, odds ratio 2.73) and more likely to have persistent AF (1.32), history of coronary artery disease (2.41) or other vascular disease (1.67), bleeding (2.11), or dementia (1.81). The odds for AP monotherapy increased with 5 years of age increments for patients ≥75 years (1.24) but decreased with age increments for patients 55-75 years (0.86). Antiplatelet monotherapy patients were less likely to have paroxysmal (0.67) or permanent AF (0.57), history of embolism (0.56), or alcohol use (0.90). With each cohort, AP monotherapy declined (P<0.0001), especially non-indicated use. AP + AC and no antithrombotic therapy were unchanged. However, even in 2015 and 2016, about 50% of AP-treated patients had no indication except AF (71% were CHA2DS2-VASc ≥2). CONCLUSION: Prescribing AP monotherapy in newly diagnosed AF has declined, but even nowadays a substantial proportion of AP-treated patients with AF have no indication for AP. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Verheugt FWA, Gao H, Al Mahmeed W, et al. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J. 2018. PMID: 29281086. doi:10.1093/eurheartj/ehx730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。